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LETTERS TO
THE EDITOR
Pressures used to flush central venous
catheters
EDITOR,—It is common practice to flush a cen-
tral venous catheter (CVC) manually when
occlusion is suspected. The manufacturers of
one silastic CVC commonly used in neonatal
units recommend a maximum flushing pres-
sure of 1.2 bars. (Vygon GmbH & Co KG.
Epicutaneo-cave-catheter product insert;
1994.) Excessive pressure may lead to CVC
rupture with associated infection, or to avul-
sion of the distal catheter. We set out to assess
whether our current practices are safe. In vitro
studies showed that the typical burst pressure
of 4 CVCs was between 5.2 and 7 bars.
We then asked 22 doctors and 14 nurses to
flush an occluded, fluid filled intravenous
pressure line attached to a manometer. Each
participant was asked to exert the maximum
pressure which they would apply when
flushing a CVC. The first 20 subjects were
asked to flush using 2.5 ml and 5 ml syringes,
and the remaining 16 subjects used only 2.5
ml syringes. Two attempts were made with
each syringe, and the higher reading was ana-
lysed. Results were expressed in geometric
mean (95% CI).
We found that:
(i) maximum pressures were significantly
lower using a 5 ml than a 2.5 ml syringe,
being 0.76 (0.56, 1.01) bars and 1.0
(0.71, 1.41) bars, respectively (p<0.01).
(ii) doctors exerted significantly higher pres-
sures than nurses (p<0.05).
(iii) for the 22 doctors using a 2.5 ml syringe
(the normal situation on our unit) the
97th centile for maximum flushing pres-
sure was 12.2 bars. Fifteen (68%) ex-
ceeded the recommended maximum
pressure and four (18%) exceeded the
likely burst pressure.
Smaller syringes exert higher output pressures.
A survey of American CVC product leaflets
reported that nearly all recommend a 10 ml
syringe as the minimum size for flushing.1
Although there would be a reduced risk of
rupture if 5 ml rather than 2.5 ml syringes were
used, we recommend that training with a
manometer should be given to all staV who are
likely to flush CVCs.We also suggest that Brit-
ish product leaflets should emphasise the haz-
ards of using smaller syringes to flush CVCs.
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Insertion of umbilical venous catheters
past the ductus venosus using the double
catheter technique
EDITOR,—We describe the use of the double
catheter technique for umbilical venous
catheterisation. Such a technique has been
described before for the cannulation of the
umbilical arteries,1 but to our knowledge has
not been described for umbilical venous cath-
eter (UVC) insertion.
One of the major problems with insertion of
UVCs is failure of the catheter to negotiate the
ductus venosus, thereby preventing it travers-
ing the inferior vena cava (IVC).2 3 If this
occurs the double catheter technique can be
used as follows. After the UVC is inserted in
the standard way and an x-ray picture shows
the catheter tip has lodged either in the portal
vein (or tributaries) or the left or right hepatic
portal veins (or branches), then a second cath-
eter is inserted in the UV whilst the first
remains in situ. The first catheter is then with-
drawn and the second fixed in place. An x-ray
picture is then repeated.
We used the double catheter technique
on two occasions in 1996: in a 4350 g term
baby with group B streptococcus sepsis. The
first UVC lodged in the liver. A second
catheter placed down the side of the first
resulted in successful negotiation of the
ductus venosus and right atrium. The second
occasion was in a shocked 31 week gestational
age infant. The first UVC was seen lodged
in the portal vein, and the second UVC
passed through the ductus venosus and IVC
to end up in the right atrium. There were no
known complications of the procedure in
either case.
Our explanation for the success of this
technique is as follows. The UV ends in the
left hepatic portal vein opposite the entrance
to the ductus venosus.2 4 Failure of the
catheter to enter the ductus venosus occurs
because, firstly it is narrowest at its origin, and
functional closure occurs here soon after
birth, and secondly the ductus venosus inlet
may not be aligned on the opposite side of the
left hepatic portal vein.2 If the catheter fails to
enter the ductus venosus it will then enter the
left hepatic portal vein and either become
lodged in the liver or in the portal vein (or its
tributaries). The first catheter takes the
course of least resistance and blocks this
undesirable route. The second catheter
inserted down the side of the first then has a
far greater chance of entering the ductus
venosus to continue on to its more desirable
location.
We believe this technique is useful for those
of us who provide neonatal intensive care.
While the adverse eVects of this technique
remain largely unstudied, it would be prudent
to use it only in those infants in whom an
umbilical venous catheter is absolutely neces-
sary.
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High concentrations of GRO-á and
MCP-1 in bronchoalveolar fluid of
infants with respiratory distress
syndrome after surfactant
EDITOR,—Recent work has related the severity
of lung damage after neonatal respiratory dis-
tress syndrome (RDS) to the early inflamma-
tory response and the degree of matrix
degradation.1 2 Although treatment with exog-
enous surfactant reduces the incidence of
bronchopulmonary dysplasia (BPD), it is not
known whether it attenuates this inflamma-
tory response.
This response has largely been investigated
by looking at cells, cytokines, and chemokines
in the bronchoalveolar lavage fluid (BAL) of
ventilated infants. Increased concentrations of
the macrophage cytokines tumour necrosis
factor á and interleukin-1â, the CC chemok-
ine MIP-1á and the CXC chemokine IL-8
have all been detected in the BAL fluid of
infants who subsequently develop BPD.1 3
Treatment with dexamethasone decreases
inflammatory cell numbers and the concentra-
tions of pro-inflammatory mediators, as well
as improving clinical outcome, although at
considerable metabolic cost.1 3
The CC chemokine MCP-1 and the CXC
chemokine GRO-á have not been investigated
in RDS. They may both have a central role in
pulmonary inflammation and they have been
implicated in the pathogenesis of experimental
pulmonary fibrosis and adult fibrotic
disease.4 5 We measured these chemokines in
the BAL fluid of 15 infants with RDS (median
birthweight 1001 g, range 700–1340 g; gesta-
tion 27 weeks, range 25–31 weeks), who had
been treated with early exogenous surfactant.
BAL was performed in the first six days of life,
after surfactant treatment, as described
before.3 Of the 15 infants, 10 had been treated
with porcine surfactant (Curosurf, Serono)
and five had been treated with synthetic
surfactant (Exosurf, Wellcome) None had
received postnatal steroids at the time of study.
Ten of the infants subsequently became
oxygen dependent at 36 weeks of equivalent
gestation, fulfilling current criteria for the
diagnosis of BPD.
The median concentration of MCP-1 was
14.72 ng/ml (95% CI 10.83–19.08) and of
GRO-á was 4.32 ng/ml (2.80–6.91). These
concentrations are far in excess of those found
in any previous study of pulmonary
inflammation.4 5 Our results suggest that the
intense early pulmonary inflammatory re-
sponse in RDS is not attenuated eVectively by
surfactant treatment, and they confirm that
four potent chemokines are produced in high
concentration in this condition. Work in
animal models has shown that pre-treatment
with cytokine antagonists can prevent experi-
mental pulmonary fibrosis, whereas subse-
quent treatment is ineVective. RDS is prob-
ably the only human inflammatory condition
in which such pretreatment is possible. We
suggest that the time has come for similar
studies of cytokine antagonism in infants ven-
tilated for RDS.
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677→CT mutation on the
methylenetetrahydrofolate reductase
gene is not a risk factor for neural tube
defects in Turkey
EDITOR,—Recent studies have shown that
periconceptual folic acid supplementation
reduces a woman’s risk of having a baby with
neural tube defects (NTD). Mothers of
infants with NTD have increased homo-
cysteine activities. People with a thermolabile
form of the enzyme 5,10 methylenetetrahy-
drofolate reductase (MTHFR) have reduced
enzyme activity and increased plasma homo-
cysteine which can be lowered by supplemen-
tal folic acid. Thermolability of the enzyme is
caused by a common mutation (677→CT) in
the MTHFR gene. In diVerent populations
the 677→CTmutation has been implicated in
susceptibility to NTD.1 We studied the
677→CT mutation as a risk factor for spine
bifida in a group of Turkish patients with
NTD, and in their parents.
Blood for mutation analysis was obtained
after written informed consent from cases with
NTDs, and their parents. The study protocol
was approved by the ethics committee of
Hacettepe University Faculty of Medicine.
The study population comprised 49 subjects
with NTDs, 40 mothers, and 33 fathers. The
control group consisted of 93 healthy adults of
Turkish origin.
We genotyped blood samples using the
polymerase chain reaction and allele specific
restriction digestion, according to the method
described by Frosst et al.2 Our data showed no
evidence for an association between the
677→Thomozygote genotype and the occur-
rence of NTD (table1). The homozygote TT
prevalences were, respectively, 8.2% for NTD
cases, and 7.5% for controls (OR 0.916, 95%
CI 0.255–3.294; p=0.893). The TT genotype
was more rare among the parents (12.3%,
n=9) of NTD cases than among the control
group (OR 1.728, 95% CIl 0.611–4.885;
p=0.298).
The prevalence of the 677→T allele diVers
among diVerent populations. It has been
noticed that the prevalence is relatively low in
controls in those countries where the
MTHFR polymorphism has been implicated
in susceptibility to NTD.3 Although the preva-
lence of the 677→T allele in the Turkish con-
trol group (0.28) is very close to that of Dutch
and Irish populations,1 where the MTHFR
mutation has been implicated in a predisposi-
tion to NTD, we found no evidence for the
association between the MTHFR mutation
and NTD in the Turkish population studied.
It has been suggested that 677→CT muta-
tion might not be responsible for a large
percentage of folic acid preventable NTD
cases1 as there are methodological problems in
the studies indicating the association between
the mutation and NTD. As the studies impli-
cating 1 4 and refuting3 5 677→CT as a risk
factor for NTD used almost identical meth-
ods, it is unlikely that the diVerent results in
diVerent populations were due to
methodological issues. We suggest that the
diVerent results reflect the real genetic varia-
tion between the populations.
The results of this study indicate that
677→CT mutation is not responsible for
NTD in Turkish patients. Further investiga-
tion is needed to elucidate the role of other
mutations in either MTHFR or other folate
related enzyme genes, which might be respon-
sible for NTD.
This study is supported by The Scientific and Tech-
nical Research Council of Turkey with a grant
encoded “SBAG-1693”.
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Quinupristin/dalfopristin in neonatal
Enterococcus faeciummeningitis
EDITOR,—Antimicrobial resistance in entero-
cocci, particularly E faecium, may greatly
restrict the choice of treatment. We report the
case of a neonate with vancomycin resistant E
faecium (VRE) meningitis successfully treated
with quinupristin/dalfopristin (a semisynthetic
injectable streptogramin) and chlorampheni-
col.
The patient underwent repair of obstructed
infradiaphragmatic total anomalous pulmo-
nary venous drainage on the first day of life.
Recovery was complicated by an episode of
necrotising enterocolitis for which cefotaxime
andmetronidazole were given. At the age of 13
days abdominal signs had resolved but the
patient was febrile. Over the next three days
six blood cultures yielded E faecium resistant
to vancomycin, amoxycillin, erythromycin,
rifampicin, and sensitive to chloramphenicol.
E faecium with the same susceptibility pattern
was grown from three intravascular lines
removed at this time. Two doses of vancomy-
cin and a single dose of gentamicin had been
given when the lines were removed. There was
only modest clinical improvement so treat-
ment with chloramphenicol (30 mg/kg/day)
was started. There was no evidence on
echocardiography of intracardiac infection.
During the first three days of chlorampheni-
col treatment three more blood cultures
yielded VRE. Teicoplanin was added—a load-
ing dose of 16 mg/kg followed by 10 mg/kg
daily. After an initial improvement the patient
again became febrile and lumbar puncture was
performed. Cerebrospinal fluid contained 16
million red cells/l and 380 million white cells/l.
Culture yielded VRE. Minimum inhibitory
concentrations of a range of antibiotics were
measured by broth microdilution technique
for the cerebrospinal fluid and blood isolates
(table 1). The dose of chloramphenicol was
increased to 75 mg/kg/day and the patient
enrolled (with informed parental consent) in a
compassionate use programme to receive
quinupristin/dalfopristin, 7 mg/kg/day in three
divided doses. Teicoplanin was discontinued.
A second sample of cerebrospinal fluid
obtained after seven days contained <1million
red cells/l, 15 million white cells/l, and was
sterile. Chloramphenicol was continued with
quinupristin/dalfopristin for 13 days. No
isolates were detected in the stools of patients
in the ward screened for the presence of VRE.
The patient made a full recovery with no
adverse events.
The baby probably developed intravascular
line infection, possibly from an intestinal
source, which failed to be controlled by
removal of the lines and administration of
chloramphenicol and teicoplanin, and this
resulted in meningitis. Although enterococcal
meningitis has been described in neonates
with bacteraemia associated with central
venous lines,1 meningitis with E faecium is
rare.2 Central nervous system infections with
VRE present a particularly diYcult therapeu-
tic problem as â lactams are inactive and
teicoplanin penetrates cerebrospinal fluid
poorly3 and in any event has little activity
against some VRE phenotypes. Chloram-
phenicol is not bactericidal and there are few
data on its use in VRE meningitis.
We were unable to measure the concentra-
tion of quinupristin/dalfopristin in the pa-
tient’s cerebrospinal fluid to assess penetra-
tion, but our clinical experience confirms that
the combination has a role in the treatment of
serious infection with vancomycin resistant E
faecium; furthermore, it complements in vitro
evidence that quinupristin/dalfopristin has an
Table 1 Genotype and allele frequencies of MTHFR 677C→T in Turkish subjects
Genotype frequencies (%) (N) Allele frequencies
C/C C/T T/T C T
NTD cases (49) 40.8 (20) 51.0 (25) 8.2 (4) 0.66 0.34
Mothers (40) 42.5 (17) 40.0 (16) 17.5 (7) 0.62 0.38
Fathers (33) 42.4 (14) 51.5 (17) 6.1 (2) 0.68 0.32
Controls (93) 50.6 (47) 41.9 (39) 7.5 (7) 0.72 0.28
Table 1 Minimum inhibitory concentration
(mg/l)
Antimicrobial Blood culture CSF isolate
Ampicillin >128 64
Erythromycin >128 >128
Vancomycin >128 128
Teicoplanin 8 2
Rifampicin 128 >128
Chloramphenicol 4 4
Ciprofloxacin >32 >32
Gentamicin 8 16
Tobramycin 64 128
Streptomycin 2048 2048
Quinupristin/
dalfopristin
0.25 0.125
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additive eVect in the presence of chloram-
phenicol.(Messick CR, Pendland SL. Abstract
EO111 presented at the 36th Interscience
Conference on Antimicrobial Agents and
Chemotherapy, New Orleans, 1996.)
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BOOK REVIEWS
Fetal & Neonatal Brain Injury.
Mechanisms, management and the risks
of practice. David K Stevenson, Philip
Sunshine, eds. [Pp 665; £175 paperback.]
Oxford University Press, 1997. ISBN
0-19-262640-X
I enjoyed delving into this book. The editors
acknowledge that the series of chapters by
individual authors had resulted in some over-
lap and repetition but that it allowed indi-
vidual prose styles to come through. That is
indeed the case and makes the narrative style
easy to read.
The foreword took me somewhat by sur-
prise: the rationale is not how we best prevent
or manage neonatal injury, nor is it a state-of-
the-art review of multicentre trials telling us
how to modify our management protocols;
rather, it is a book for the courtroom “where
these complex neurologic issues are regularly
publicly debated. Opposing neuroscientists
are in great demand as expert witnesses.” I
would question whether this book really does
serve that purpose. It might have achieved it
rather better had some of the subjects been
reviewed as a critical evaluation of the
available scientifically valid studies. For exam-
ple, there is scant recognition of the debate
that rages over the treatment of neonatal elec-
trographic seizures without clinical accompa-
niment. Do we really know whether treatment
of these is of definite benefit?
The final chapter on the appropriateness of
intensive care application made particularly
interesting reading and especially so in the
light of the recently published Royal College
of Paediatrics and Child Health guidelines on
Withholding or withdrawing life saving treatment
in children. It seems clear that financial consid-
erations are beginning to figure more promi-
nently in these matters, and in this country we
are behind in that debate. The author admits
that, in the USA, practical considerations such
as litigation or even adverse media publicity
may prevail over moral and medical judgment
of physicians and, hence, parents.
This book made me think about neonatal
brain injury in some detail and examine my
own understanding and practice. To this end it
will be valuable to those of us privileged to be
invited to attend the courtroom to discuss
such issues. Of course, not all the answers are
there: it is for paediatricians to provide those
answers through peer reviewed research and
not let legal precedents take the lead.
MARTIN KIRKPATRICK
Consultant paediatric neurologist
Ninewells Hospital and Medical School, Dundee
An atlas of neonatal brain sonography.
P Govaert, L S de Vries eds. (Pp 363; £50
hardback) Cambridge University Press, 1997.
ISBN 1-898683-09-3
In the early 1970s intracranial haemorrhage in
prematurely born babies was thought to be
predominantly fatal, with the few survivors
developing post haemorrhagic hydrocephalus.
With the introduction of computed tomogra-
phy brain scanning of surviving premature
infants, it was found that far from being fatal,
most infants who had intraventricular haem-
orrhage survived—and often with few or no
abnormal neurological signs. In the late 1970s
real-time ultrasonography was shown to be a
convenient, safe, and reproducible technique
for imaging the newborn baby’s brain and
improvements in technology now mean that
every neonatal unit in the developed world has
access to high quality ultrasound imaging.
There can be little doubt that this title rep-
resents the definitive work on neonatal cranial
ultrasound. The authors have had extensive
experience in the use of ultrasound scanning
the neonatal brain for almost as long as ultra-
sound has been used to investigate intracranial
pathology on the neonatal unit; their com-
bined experience is most impressive. The book
covers every aspect of ultrasound brain imag-
ing currently available and discusses variations
of every form of pathology evident by this
technique.
The illustrations are extremely good and
considerable pains have been taken to ensure
that they are reproduced to best eVect. One
problem, as the authors readily admit, is
knowing the clinical significance of some of
the appearances they describe. Do they repre-
sent pathology or are they normal or develop-
mental variants?
Unfortunately, the strength of this book is
also its weakness. By showing examples of so
much pathology, with many of the abnormali-
ties being relatively subtle, begs the question
of whether more information could be ob-
tained from other imaging modalities. In
recent years magnetic resonance has become a
very important technique for imaging the
brain, and to some extent, ultrasound and
magnetic resonance are complementary. In
other indications, particularly in mature in-
fants, magnetic resonance is the best tech-
nique for recognising many forms of pathol-
ogy. By concentrating on the minutiae of
ultrasound imaging, the reader misses the
point as to what is the best way of diagnosing
abnormalities. The art of modern imaging is
not to expect a great level of skill in one tech-
nique but the best selection of imaging tools
from the range of techniques available. It is a
great pity that this excellent book did not
include more magnetic resonance or com-
puted tomography images with comments on
the advantages and disadvantages of each. The
authors acknowledge this criticism in the sec-
ond sentence of their preface, but do not
explain why they did not extend the scope of
the book.
This book tells you everything you need to
know about neonatal cranial imaging with
superb illustrations, but it does not tell the cli-
nician what s/he really needs to know, which is
the limitation of ultrasound as a diagnostic
technique and how other modalities can aid in
more accurate diagnosis.
MALCOLM LEVENE
Professor of Paediatrics, General Infirmary, Leeds
Neonatal hematology and immunology
III. J A Bellanti, R Bracci, G Prindull, M
Xanthou, eds. (Pp 252; $US 172 hardback).
Elsevier Science, 1997. ISBN 0-444-82573-8
This book is a compilation of papers presented
at the third meeting of the European Society
for Pediatric Haematology and Immunology
in 1996. As the editors themselves admit, the
book does not cover the entire area of either
haematology or immunology but “reflects the
particular interests of the colleagues who
attended the symposium.” This raises the
important question as to whether these
participants were indeed invited speakers rep-
resenting their expert areas or whether they
represent authors who had submitted ab-
stracts to the symposium.
The book is divided in two sections—
immunology and haematology—with each
section further divided into five areas of inter-
est. The immunology section includes micro-
bial host-cell interaction, immunological en-
hancement of neonates, viral infections and
food allergy. The haematology section in-
cludes the use of erythropoietin, coagulation,
stem cell function, and immunologically
mediated cytopenia and anaemia.
Each subdivision has three to four short
papers of three to six pages including refer-
ences. Some important subject areas are
covered, including the use of immunoglobu-
lins in neonatal sepsis, the use of erythropoi-
etin for anaemia of prematurity, and the use of
G-CSF for neutropenia. The quality varies
considerably between chapters. Some argue
rather strongly for the use of their selected
therapeutic modality despite insuYcient pub-
lished data while others argue more objec-
tively.
It was interesting to read about the use of
immunoglobulins in respiratory syncytial
virus in post-neonatal infants (surprisingly in a
neonatal book) but rather repetitive to read for
the third time in three consecutive chapters
the adverse eVects observed with formalin
inactivated RSV vaccine when it was intro-
duced in the 1960s.
Furthermore, the chapters have varying
fonts as well as styles, making this book rather
diYcult to read. The large number of spelling
mistakes only makes this worse. The style for
each chapter presumably reflects that of the
author’s with no editorial uniformity. Help-
fully, some chapters have a summary or
abstract, but most do not.
The book is unlikely to be of use to the gen-
eral paediatrician or neonatologist as the
introduction does not give suYcient infor-
mation on the topic being discussed. Nor do
the chapters give suYcient detail to permit the
reader to decide whether to use the treatment
or intervention being discussed.
SAILESH KOTECHA
Senior lecturer in child health
University of Leicester
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